Get the Prostate Cancer Patient Guide as a digital download or free mailed copy.

Click here.


Breaking News: First-in-Class Radioligand Therapy Approved for Advanced Prostate Cancer

What this means for patients: Today, a new treatment known as 177lutetium-PSMA-617 (Lu-PSMA; trade name Pluvicto®) was approved by the FDA for certain patients with advanced prostate cancer. This medicine delivers a small dose of radiation attached to a molecule that specifically binds to prostate cancer cells. It has been shown to. Read More


Highlights of ASCO GU 2022, Part 1

Combination treatments for metastatic disease Clinicians and researchers gathered last month at the American Society of Clinical Oncology Genitourinary Cancers Symposium (ASCO GU) — some in-person in San Francisco, some tuning in virtually. Hundreds of presentations covered advances in screening, diagnosis, treatment, monitoring, and survivorship in prostate and other GU. Read More